Related Experiment Videos
Clinical trials on the efficacy of pharmacologic intervention reducing mortality from cardiovascular diseases
Insights
Adrenergic beta blockers and aspirin aid secondary prevention of heart attack mortality. Rigorous hypertension treatment, especially for mild cases, is crucial for primary prevention before organ damage occurs.
Area of Science:
- Cardiology
- Clinical Trials
- Preventive Medicine
Background:
- Ischemic heart disease and cerebrovascular disease pose significant health risks.
- Secondary prevention strategies are vital for patients post-myocardial infarction or unstable angina.
- Primary prevention focuses on mitigating risks before disease onset.
Purpose of the Study:
- To review clinical trial data on secondary prevention of ischemic heart disease.
- To evaluate the efficacy of hypertension treatment in primary prevention of cardiovascular and cerebrovascular diseases.
Main Methods:
- Analysis of clinical trial results for secondary prevention drugs (beta blockers, aspirin, dipyridamole).
- Review of data from the Hypertension Detection and Follow-Up Program and the Australian Therapeutic Trial in Mild Hypertension for primary prevention.
Main Results:
- Long-term use of beta blockers and platelet-active drugs reduces mortality post-myocardial infarction and prevents recurrence.
- Rigorous hypertension treatment, initiated early, is effective in primary prevention, even for mild hypertension.
- Treatment efficacy is highest before target organ damage, like left ventricular hypertrophy, is evident.
Conclusions:
- Adrenergic beta blockers and platelet-active drugs are recommended for secondary prevention of ischemic heart disease.
- Early and rigorous management of hypertension is essential for primary prevention of ischemic and cerebrovascular diseases.
Abstract:
Results of recent clinical trials on secondary prevention of ischemic heart disease indicate that judicious, long-term administration of adrenergic beta blockers and platelet-active drugs such as aspirin and Persantine (dipyridamole) would seem to yield protection against mortality associated with acute myocardial infarction, including sudden death. These drugs are beneficial also in prevention of recurrent myocardial infarction, especially among patients with unstable angina. These drugs should be considered as soon as the diagnosis of myocardial infarction or unstable angina is confirmed clinically. In terms of primary prevention of ischemic heart disease and cerebrovascular disease (stroke), the results of the Hypertension Detection and Follow-Up Program provide an excellent set of data on the efficacy of rigorous treatment of hypertension, especially those with mild hypertension. To be effective, treatment must start before there is evidence of target end organ damage, such as left ventricular hypertrophy. Recent data from the Australian Therapeutic Trial in Mild Hypertension also confirms these findings.